Erin E. Burkhart - 10 Mar 2026 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Reporting relationship: SVP, Controllership
Issuer ticker: GILD
Reported as of: 10 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Mar 2026, 16:37:46 UTC
Prior SEC filing: 23 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Amy Kim by Power of Attorney for Erin E. Burkhart

Key filing fact

Erin E. Burkhart filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 12 Mar 2026.

Key facts

This page summarizes Erin E. Burkhart's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Mar 2026, 16:37.

Change

Previous filing in this sequence was filed on 23 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001927648 Primary reporting owner

Burkhart Erin

Relationship: SVP, Controllership
Address: 333 LAKESIDE DRIVE, FOSTER CITY
Signature: /s/ Amy Kim by Power of Attorney for Erin E. Burkhart
Signature date: 12 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GILD transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +2,355
Change %: +26%
Price
Shares after: 11,245
Date: 10 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,355
Exercise price
Footnotes: F1, F2

GILD transaction Derivative

Non-qualified Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,455
Change %
Price: $0.000000^*
Shares after: 5,455
Date: 10 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,455
Exercise price: $148.56
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Footnote F2

The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Footnote F3

The stock options have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.